Mirum Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher Peetz
- Full Time Employees
- 334
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 950 Tower Lane Foster City CA United States of America 94404
- IPO Date
- Jul 18, 2019
- CIK
- 0001759425
- Website
- mirumpharma.com
- Similar Companies
- Business
- Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for severe rare and orphan diseases, particularly those affecting the liver. The company’s flagship product, LIVMARLI (maralixibat), an ileal bile acid transporter (IBAT) inhibitor, is approved in the United States and Europe for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) aged three months and older (two months and older in Europe). LIVMARLI also holds U.S. approval for cholestatic pruritus in progressive familial intrahepatic cholestasis (PFIC) patients 12 months and older, and European approval for PFIC patients three months and older. Beyond LIVMARLI, Mirum is advancing Volixibat, another IBAT inhibitor, through late-stage clinical studies for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), having reported positive interim results for PBC showing significant improvements in pruritus and fatigue. The company's pipeline further includes CHOLBAM (cholic acid) capsules for bile acid synthesis disorders and CHENODAL (chenodiol) tablets for cerebrotendinous xanthomatosis (CTX), both FDA-approved. Mirum also has MRM-3379, a PDE4D inhibitor, in Phase 2 development for Fragile X syndrome. Mirum Pharmaceuticals, established in 2018 and headquartered in Foster City, California, generates revenue primarily from product sales across key markets including the United States and Europe. The company reported strong financial performance in 2024 and Q3 2025, with increasing product sales and a move to net profitability, leading to raised revenue guidance for 2025.
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
Mirum Pharmaceuticals Enters Catalyst-Rich Stretch as LIVMARLI Sales and Pipeline Advance
Mirum Pharmaceuticals to Present Data Showcasing Leadership in Rare Liver Diseases at the EASL International Liver Congress 2026
Mirum Pharma: A Rare Disease Growth Story to Watch
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals Prices $600.0 Million Convertible Senior Notes Offering; Refinances a Portion of 2029 Convertible Notes
Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering
Mirum Pharmaceuticals: A Rare Disease Platform Becoming Bigger Than Its First Franchise
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
Mirum's Q1 Earnings & Revenues Beat Estimates, 2026 View Raised
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q1 Earnings
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Beats Revenue Estimates
Mirum Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta Transcript
Mirum's rare liver disease drug meets main goal in mid-stage study
Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets
Mirum Pharmaceuticals Announces Primary Endpoint Met in VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the VISTAS Study of Volixibat in Patients with Primary Sclerosing Cholangitis on May 4, 2026